Approved as a first- or later-line therapy for a broad range of patients with advanced CSCC1

Characteristics of patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation, and who enrolled in Study 15401

Chart, clinical study 1540 patient characteristics: mCSCC or laCSCC (N=193)
66% of patients received LIBTAYO as a first-line systemic therapy

66%
of patients received LIBTAYO
as first-line systemic therapy3

90% of patients had received prior cancer-related surgery

90%
of patients had received
prior cancer-related surgery1

68% of patients had received prior radiotherapy

68%
of patients had received
prior radiotherapy1

23% of patients with mCSCC had only nodal metastases

23%
of patients with mCSCC
had only nodal metastases1

77% of patients with mCSCC had distant metastases

77%
of patients with mCSCC
had distant metastases1

No PD-L1 testing is required before starting LIBTAYO for advanced CSCC1,5

LIBTAYO is approved for a wide variety of patients with advanced CSCC1

Situations when surgery may not be appropriate and situations when radiation may not be appropriate

CSCC=cutaneous squamous cell carcinoma; ECOG=Eastern Cooperative Oncology Group; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; PD-L1=programmed death ligand 1; PS=performance status.

Please see full Prescribing Information.
The focus of this video is on identifying patients with advanced CSCC who are not candidates for curative surgery or curative radiation, ans should be considered for systemic therapy and consultation with a medical oncologist.
Chapter 1 Dr Whitman's and Dr Cohen's introductions
Chapter 2 Situations where surgery may not be appropriate for patients with locally advanced CSCC
Chapter 3 Situations Where radiation may not be appropriate for patients with locally advanced CSCC
Chapter 4 Multidisciplinary approach to assessing treatment options for locally advanced CSCC
Chapter 5 Overview of LIBTAYO
Chapter 6 Patient case study (70-year-old male with locally advanced CSCC)
Chapter 7 Important Safety Information
Chapter 8 References

References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02760498. Updated January 26, 2021. Accessed March 24, 2021. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months. Poster presented at: European Association of Dermato Oncology Congress 2021 Virtual Scientific Meeting. 15-17 April 2021. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097. Updated June 25, 2020. Accessed January 19, 2021. 5. Data on file. Regeneron Pharmaceuticals, Inc. 6. Alam M, Armstrong A, Baum C, et al; Work Group, Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578.